Skip to content
RNAWiki
Checking…
All public datasets

Public dataset

Recorded enzyme and transporter findings by polarity

Inspect every admitted source sentence for an exact medicine, enzyme or transporter, and recorded role, with assertions, denials, and unresolved polarity counted separately.

What this does not mean: This is not a drug interaction checker. A denial applies only to the named medicine, role, counterparty, conditions, and source sentence; it is not proof of no interaction and is not dosing or treatment advice.
Public rows
8,404
Generated
Schema version
1.3.0

Coverage

What this run contains

Medicine–counterparty–role groups
8,404
Source sentence records
20,358
Asserted sentences
4,700
Denied sentences
7,494
Polarity not recorded
8,164
Medicines represented
755
Counterparties represented
36
Corpus records considered
9,855
All corpus records were checked; a record without a documented counterparty cannot produce a row in this projection.
inducer groups
617
inhibitor groups
3,131
not_recorded groups
3,074
substrate groups
1,582

Method

How the rows were made

  1. A deterministic parser reads recorded FDA-label excerpts for named enzymes and transporters.
  2. A mention is admitted only when the stored excerpt contains the recorded counterparty, allowing letter-case differences only.
  3. Every admitted mention is grouped by exact medicine slug, recorded counterparty spelling, and exact role. A missing role remains NOT_RECORDED rather than being assigned to another group.
  4. Each sentence carries the exact source version and effective date when recorded; the API serializes null and the page says not recorded when either is absent.
  5. The API paginates groups. Within each returned group, sentences is the complete untruncated list used by the three polarity counts.

Limits

Read these before using a row

  • A recorded role is a mechanistic statement copied from a descriptive label section. It is not a clinical interaction, and nothing in this dataset describes what happens when a person is exposed to two medicines at once.
  • This dataset holds no relation between one medicine and another. Counts are per counterparty; the medicines naming a counterparty are listed with their sentences and are never paired, ranked against each other or compared.
  • ICH M12 states that no potency classification system exists for transporters or for non-CYP enzymes, so no strong, moderate or weak vocabulary is applied to any counterparty here. The tallies count records, not strength.
  • A counterparty with a high count is one that labels document often. Documentation frequency is not importance: US labelling asks for some enzymes to be characterised far more routinely than others, and that requirement is part of what these counts measure.
  • 40.1% of admitted mentions carry no role. The sentence named more than one role and the parser left the question open rather than attaching a guess, so a role tally is a count of sentences that settled the question, not of medicines for which it is settled.
  • Recorded spellings are counted separately and never merged. P-GP, PGP and P-GLYCOPROTEIN are three entries in this dataset because they are three strings in the corpus; whether they name one thing is a question for a person, and prefix relationships are reported as questions rather than resolved.
  • 9088 of 9855 records name no enzyme or transporter at all. That is an absence of recorded text in the sources fetched for those records. It is neither reassurance nor alarm about the medicines concerned.
  • 20358 of 20358 admitted mentions come from records the deterministic label parser produced, where no person chose the value or wrote its measurement context. The sentence is stored with each one so a reader can check it.
  • The uniform reference for concentration allocates the same 20358 mentions over the same 36 counterparties by chance. Labels are not written that way, so the reference shows only that the observed spread is not a consequence of how many mentions there are.
  • The public rows enumerate documentation about one medicine and one named counterparty. They never create medicine-to-medicine pairs and cannot answer whether two medicines interact.
  • A NOT_RECORDED role or polarity remains unresolved. It is never folded into an assertion or a denial.
  • Each returned group includes every admitted source sentence for checking, but the full source document remains authoritative.

Provenance

Source examples

Abacavir · CYP3A4 inhibitor

2 asserted · 2 denied · 0 polarity not recorded

FDA_LABEL:5676d391-f9a4-44be-9604-954b3d8d0e2b (opens source in a new tab)
In vitro experiments reveal that abacavir does not inhibit human CYP3A4, CYP2D6, or CYP2C9 activity at clinically relevant concentrations.

Abacavir · BCRP substrate

0 asserted · 4 denied · 0 polarity not recorded

FDA_LABEL:5676d391-f9a4-44be-9604-954b3d8d0e2b (opens source in a new tab)
Based on in vitro study results, abacavir at therapeutic drug exposures is not expected to affect the pharmacokinetics of drugs that are substrates of the following transporters: organic anion transporter polypeptide (OATP)1B1/3, breast cancer resistance protein (BCRP) or P-glycoprotein (P-gp), organic cation transporter (OCT)1, OCT2, or multidrug and toxic extrusion protein (MATE)1 and MATE2-K.

Abacavir · CYP2C9 not_recorded

0 asserted · 0 denied · 2 polarity not recorded

FDA_LABEL:5676d391-f9a4-44be-9604-954b3d8d0e2b (opens source in a new tab)
Abacavir did not inhibit or induce other CYP enzymes (such as CYP2C9, or CYP2D6).

Artifact used for this view: data/agents/current/enzyme-and-transporter-documentation.json. The reader resolves the current run first and uses the checked-in compatibility run only when a current artifact is absent.

Schema

Fields in the public projection

FieldTypeMeaning
medicineSlugstringStable RNAWiki medicine route key.
medicineNamestringRecorded medicine name; not normalized for display style.
counterpartystringThe exact recorded counterparty spelling.
rolestringSUBSTRATE, INHIBITOR, INDUCER, or NOT_RECORDED when the sentence did not settle one role.
assertedCountnumberSentence records whose polarity is ASSERTED.
deniedCountnumberSentence records whose polarity is NEGATED.
polarityNotRecordedCountnumberSentence records for which the parser did not settle assertion or denial.
sentencessentence[]Every admitted sentence for this group, with polarity, section, source identity, source version/effective date or explicit absence, retrieval date, and exact excerpt. The list is not truncated.

Reader

Search and filter the rows

Case-insensitive text search over the public fields named for this dataset.

Exact recorded role.

Exact recorded counterparty spelling.

Clear

Showing 2,521–2,530 of 8,404 matching rows. Filters and search terms remain attached when you move between pages or open the API view.

  1. Projected row 2521

    Medicine slug
    emtricitabine
    Medicine name
    Emtricitabine
    Enzyme or transporter
    CYP2C9
    Role
    INHIBITOR
    Asserted sentences
    0
    Denied sentences
    2
    Polarity not recorded
    0
    Complete sentence records
    1. NEGATEDpharmacokineticsRetrieved 2026-08-30
      FDA_LABEL:d6599395-3944-44f9-97f2-e0424c6b6a1f (opens source in a new tab)

      Emtricitabine label

      Version not recorded · Effective date not recorded

      Assessment of Drug Interactions At concentrations up to 14-fold higher than those observed in vivo, FTC did not inhibit in vitro drug metabolism mediated by any of the following human CYP isoforms: CYP1A2, CYP2A6, CYP2B6, CYP2C9, CYP2C19, CYP2D6, and CYP3A4.
    2. NEGATEDclinical_pharmacologyRetrieved 2026-08-30
      FDA_LABEL:d6599395-3944-44f9-97f2-e0424c6b6a1f (opens source in a new tab)

      Emtricitabine label

      Version not recorded · Effective date not recorded

      Assessment of Drug Interactions At concentrations up to 14-fold higher than those observed in vivo, FTC did not inhibit in vitro drug metabolism mediated by any of the following human CYP isoforms: CYP1A2, CYP2A6, CYP2B6, CYP2C9, CYP2C19, CYP2D6, and CYP3A4.

  2. Projected row 2522

    Medicine slug
    emtricitabine
    Medicine name
    Emtricitabine
    Enzyme or transporter
    CYP2D6
    Role
    INHIBITOR
    Asserted sentences
    0
    Denied sentences
    2
    Polarity not recorded
    0
    Complete sentence records
    1. NEGATEDpharmacokineticsRetrieved 2026-08-30
      FDA_LABEL:d6599395-3944-44f9-97f2-e0424c6b6a1f (opens source in a new tab)

      Emtricitabine label

      Version not recorded · Effective date not recorded

      Assessment of Drug Interactions At concentrations up to 14-fold higher than those observed in vivo, FTC did not inhibit in vitro drug metabolism mediated by any of the following human CYP isoforms: CYP1A2, CYP2A6, CYP2B6, CYP2C9, CYP2C19, CYP2D6, and CYP3A4.
    2. NEGATEDclinical_pharmacologyRetrieved 2026-08-30
      FDA_LABEL:d6599395-3944-44f9-97f2-e0424c6b6a1f (opens source in a new tab)

      Emtricitabine label

      Version not recorded · Effective date not recorded

      Assessment of Drug Interactions At concentrations up to 14-fold higher than those observed in vivo, FTC did not inhibit in vitro drug metabolism mediated by any of the following human CYP isoforms: CYP1A2, CYP2A6, CYP2B6, CYP2C9, CYP2C19, CYP2D6, and CYP3A4.

  3. Projected row 2523

    Medicine slug
    emtricitabine
    Medicine name
    Emtricitabine
    Enzyme or transporter
    CYP3A4
    Role
    INHIBITOR
    Asserted sentences
    0
    Denied sentences
    2
    Polarity not recorded
    0
    Complete sentence records
    1. NEGATEDpharmacokineticsRetrieved 2026-08-30
      FDA_LABEL:d6599395-3944-44f9-97f2-e0424c6b6a1f (opens source in a new tab)

      Emtricitabine label

      Version not recorded · Effective date not recorded

      Assessment of Drug Interactions At concentrations up to 14-fold higher than those observed in vivo, FTC did not inhibit in vitro drug metabolism mediated by any of the following human CYP isoforms: CYP1A2, CYP2A6, CYP2B6, CYP2C9, CYP2C19, CYP2D6, and CYP3A4.
    2. NEGATEDclinical_pharmacologyRetrieved 2026-08-30
      FDA_LABEL:d6599395-3944-44f9-97f2-e0424c6b6a1f (opens source in a new tab)

      Emtricitabine label

      Version not recorded · Effective date not recorded

      Assessment of Drug Interactions At concentrations up to 14-fold higher than those observed in vivo, FTC did not inhibit in vitro drug metabolism mediated by any of the following human CYP isoforms: CYP1A2, CYP2A6, CYP2B6, CYP2C9, CYP2C19, CYP2D6, and CYP3A4.

  4. Projected row 2524

    Medicine slug
    enasidenib
    Medicine name
    Enasidenib
    Enzyme or transporter
    BCRP
    Role
    INHIBITOR
    Asserted sentences
    0
    Denied sentences
    2
    Polarity not recorded
    0
    Complete sentence records
    1. NEGATEDpharmacokineticsRetrieved 2026-08-30
      FDA_LABEL:a5b4cdf0-3fa8-4c6c-80f6-8d8a00e3a5b6 (opens source in a new tab)

      Enasidenib label

      Version not recorded · Effective date not recorded

      AGI-16903 inhibits BCRP, OAT1, OAT3, OATP1B1, and OCT2, but not P-gp, MRP2, or OATP1B3.
    2. NEGATEDclinical_pharmacologyRetrieved 2026-08-30
      FDA_LABEL:a5b4cdf0-3fa8-4c6c-80f6-8d8a00e3a5b6 (opens source in a new tab)

      Enasidenib label

      Version not recorded · Effective date not recorded

      AGI-16903 inhibits BCRP, OAT1, OAT3, OATP1B1, and OCT2, but not P-gp, MRP2, or OATP1B3.

  5. Projected row 2525

    Medicine slug
    enasidenib
    Medicine name
    Enasidenib
    Enzyme or transporter
    BCRP
    Role
    SUBSTRATE
    Asserted sentences
    4
    Denied sentences
    2
    Polarity not recorded
    0
    Complete sentence records
    1. ASSERTEDpharmacokineticsRetrieved 2026-08-30
      FDA_LABEL:a5b4cdf0-3fa8-4c6c-80f6-8d8a00e3a5b6 (opens source in a new tab)

      Enasidenib label

      Version not recorded · Effective date not recorded

      OATP1B1, OATP1B3, and BCRP Substrates: Rosuvastatin (an OATP1B1, OATP1B3, and BCRP substrate) AUC 0-INF and C max increased by 244% and 366%, respectively, following concomitant use of multiple doses of IDHIFA 100 mg with a single oral dose of rosuvastatin 10 mg.
    2. ASSERTEDpharmacokineticsRetrieved 2026-08-30
      FDA_LABEL:a5b4cdf0-3fa8-4c6c-80f6-8d8a00e3a5b6 (opens source in a new tab)

      Enasidenib label

      Version not recorded · Effective date not recorded

      AGI-16903 is a substrate of both P-gp and BCRP.
    3. ASSERTEDclinical_pharmacologyRetrieved 2026-08-30
      FDA_LABEL:a5b4cdf0-3fa8-4c6c-80f6-8d8a00e3a5b6 (opens source in a new tab)

      Enasidenib label

      Version not recorded · Effective date not recorded

      OATP1B1, OATP1B3, and BCRP Substrates: Rosuvastatin (an OATP1B1, OATP1B3, and BCRP substrate) AUC 0-INF and C max increased by 244% and 366%, respectively, following concomitant use of multiple doses of IDHIFA 100 mg with a single oral dose of rosuvastatin 10 mg.
    4. ASSERTEDclinical_pharmacologyRetrieved 2026-08-30
      FDA_LABEL:a5b4cdf0-3fa8-4c6c-80f6-8d8a00e3a5b6 (opens source in a new tab)

      Enasidenib label

      Version not recorded · Effective date not recorded

      AGI-16903 is a substrate of both P-gp and BCRP.
    5. NEGATEDpharmacokineticsRetrieved 2026-08-30
      FDA_LABEL:a5b4cdf0-3fa8-4c6c-80f6-8d8a00e3a5b6 (opens source in a new tab)

      Enasidenib label

      Version not recorded · Effective date not recorded

      Transporter Systems: Enasidenib is not a substrate for P-glycoprotein (P-gp) or breast cancer resistance protein (BCRP).
    6. NEGATEDclinical_pharmacologyRetrieved 2026-08-30
      FDA_LABEL:a5b4cdf0-3fa8-4c6c-80f6-8d8a00e3a5b6 (opens source in a new tab)

      Enasidenib label

      Version not recorded · Effective date not recorded

      Transporter Systems: Enasidenib is not a substrate for P-glycoprotein (P-gp) or breast cancer resistance protein (BCRP).

  6. Projected row 2526

    Medicine slug
    enasidenib
    Medicine name
    Enasidenib
    Enzyme or transporter
    CYP1A2
    Role
    INHIBITOR
    Asserted sentences
    2
    Denied sentences
    0
    Polarity not recorded
    0
    Complete sentence records
    1. ASSERTEDpharmacokineticsRetrieved 2026-08-30
      FDA_LABEL:a5b4cdf0-3fa8-4c6c-80f6-8d8a00e3a5b6 (opens source in a new tab)

      Enasidenib label

      Version not recorded · Effective date not recorded

      The metabolite AGI-16903 inhibits CYP1A2, CYP2B6, CYP2C8, CYP2C9, CYP2C19, and CYP2D6.
    2. ASSERTEDclinical_pharmacologyRetrieved 2026-08-30
      FDA_LABEL:a5b4cdf0-3fa8-4c6c-80f6-8d8a00e3a5b6 (opens source in a new tab)

      Enasidenib label

      Version not recorded · Effective date not recorded

      The metabolite AGI-16903 inhibits CYP1A2, CYP2B6, CYP2C8, CYP2C9, CYP2C19, and CYP2D6.

  7. Projected row 2527

    Medicine slug
    enasidenib
    Medicine name
    Enasidenib
    Enzyme or transporter
    CYP1A2
    Role
    NOT_RECORDED
    Asserted sentences
    0
    Denied sentences
    0
    Polarity not recorded
    4
    Complete sentence records
    1. NOT_RECORDEDpharmacokineticsRetrieved 2026-08-30
      FDA_LABEL:a5b4cdf0-3fa8-4c6c-80f6-8d8a00e3a5b6 (opens source in a new tab)

      Enasidenib label

      Version not recorded · Effective date not recorded

      Metabolism of enasidenib is mediated by multiple cytochrome P450 (CYP) enzymes (e.g., CYP1A2, CYP2B6, CYP2C8, CYP2C9, CYP2C19, CYP2D6, and CYP3A4), and by multiple UDP glucuronosyl transferases (UGTs) (e.g., UGT1A1, UGT1A3, UGT1A4, UGT1A9, UGT2B7, and UGT2B15) in vitro.
    2. NOT_RECORDEDpharmacokineticsRetrieved 2026-08-30
      FDA_LABEL:a5b4cdf0-3fa8-4c6c-80f6-8d8a00e3a5b6 (opens source in a new tab)

      Enasidenib label

      Version not recorded · Effective date not recorded

      Further metabolism of the metabolite AGI-16903 is also mediated by multiple enzymes (e.g., CYP1A2, CYP2C19, CYP3A4, UGT1A1, UGT1A3, and UGT1A9) in vitro.
    3. NOT_RECORDEDclinical_pharmacologyRetrieved 2026-08-30
      FDA_LABEL:a5b4cdf0-3fa8-4c6c-80f6-8d8a00e3a5b6 (opens source in a new tab)

      Enasidenib label

      Version not recorded · Effective date not recorded

      Metabolism of enasidenib is mediated by multiple cytochrome P450 (CYP) enzymes (e.g., CYP1A2, CYP2B6, CYP2C8, CYP2C9, CYP2C19, CYP2D6, and CYP3A4), and by multiple UDP glucuronosyl transferases (UGTs) (e.g., UGT1A1, UGT1A3, UGT1A4, UGT1A9, UGT2B7, and UGT2B15) in vitro.
    4. NOT_RECORDEDclinical_pharmacologyRetrieved 2026-08-30
      FDA_LABEL:a5b4cdf0-3fa8-4c6c-80f6-8d8a00e3a5b6 (opens source in a new tab)

      Enasidenib label

      Version not recorded · Effective date not recorded

      Further metabolism of the metabolite AGI-16903 is also mediated by multiple enzymes (e.g., CYP1A2, CYP2C19, CYP3A4, UGT1A1, UGT1A3, and UGT1A9) in vitro.

  8. Projected row 2528

    Medicine slug
    enasidenib
    Medicine name
    Enasidenib
    Enzyme or transporter
    CYP1A2
    Role
    SUBSTRATE
    Asserted sentences
    2
    Denied sentences
    0
    Polarity not recorded
    0
    Complete sentence records
    1. ASSERTEDpharmacokineticsRetrieved 2026-08-30
      FDA_LABEL:a5b4cdf0-3fa8-4c6c-80f6-8d8a00e3a5b6 (opens source in a new tab)

      Enasidenib label

      Version not recorded · Effective date not recorded

      Drug Interaction Studies Clinical Studies CYP1A2 Substrates: Caffeine (a sensitive CYP1A2 substrate) AUC 0-INF and C max increased by 655% and 18%, respectively, following concomitant use of multiple doses of IDHIFA 100 mg with a single oral dose of 100 mg caffeine.
    2. ASSERTEDclinical_pharmacologyRetrieved 2026-08-30
      FDA_LABEL:a5b4cdf0-3fa8-4c6c-80f6-8d8a00e3a5b6 (opens source in a new tab)

      Enasidenib label

      Version not recorded · Effective date not recorded

      Drug Interaction Studies Clinical Studies CYP1A2 Substrates: Caffeine (a sensitive CYP1A2 substrate) AUC 0-INF and C max increased by 655% and 18%, respectively, following concomitant use of multiple doses of IDHIFA 100 mg with a single oral dose of 100 mg caffeine.

  9. Projected row 2529

    Medicine slug
    enasidenib
    Medicine name
    Enasidenib
    Enzyme or transporter
    CYP2B6
    Role
    INDUCER
    Asserted sentences
    2
    Denied sentences
    0
    Polarity not recorded
    0
    Complete sentence records
    1. ASSERTEDpharmacokineticsRetrieved 2026-08-30
      FDA_LABEL:a5b4cdf0-3fa8-4c6c-80f6-8d8a00e3a5b6 (opens source in a new tab)

      Enasidenib label

      Version not recorded · Effective date not recorded

      Enasidenib induces CYP2B6.
    2. ASSERTEDclinical_pharmacologyRetrieved 2026-08-30
      FDA_LABEL:a5b4cdf0-3fa8-4c6c-80f6-8d8a00e3a5b6 (opens source in a new tab)

      Enasidenib label

      Version not recorded · Effective date not recorded

      Enasidenib induces CYP2B6.

  10. Projected row 2530

    Medicine slug
    enasidenib
    Medicine name
    Enasidenib
    Enzyme or transporter
    CYP2B6
    Role
    INHIBITOR
    Asserted sentences
    4
    Denied sentences
    0
    Polarity not recorded
    0
    Complete sentence records
    1. ASSERTEDpharmacokineticsRetrieved 2026-08-30
      FDA_LABEL:a5b4cdf0-3fa8-4c6c-80f6-8d8a00e3a5b6 (opens source in a new tab)

      Enasidenib label

      Version not recorded · Effective date not recorded

      In Vitro Studies CYP and UGT Enzymes: Enasidenib inhibits CYP2B6 and UGT1A1.
    2. ASSERTEDpharmacokineticsRetrieved 2026-08-30
      FDA_LABEL:a5b4cdf0-3fa8-4c6c-80f6-8d8a00e3a5b6 (opens source in a new tab)

      Enasidenib label

      Version not recorded · Effective date not recorded

      The metabolite AGI-16903 inhibits CYP1A2, CYP2B6, CYP2C8, CYP2C9, CYP2C19, and CYP2D6.
    3. ASSERTEDclinical_pharmacologyRetrieved 2026-08-30
      FDA_LABEL:a5b4cdf0-3fa8-4c6c-80f6-8d8a00e3a5b6 (opens source in a new tab)

      Enasidenib label

      Version not recorded · Effective date not recorded

      In Vitro Studies CYP and UGT Enzymes: Enasidenib inhibits CYP2B6 and UGT1A1.
    4. ASSERTEDclinical_pharmacologyRetrieved 2026-08-30
      FDA_LABEL:a5b4cdf0-3fa8-4c6c-80f6-8d8a00e3a5b6 (opens source in a new tab)

      Enasidenib label

      Version not recorded · Effective date not recorded

      The metabolite AGI-16903 inhibits CYP1A2, CYP2B6, CYP2C8, CYP2C9, CYP2C19, and CYP2D6.

Access

Query or download the projection

View this filtered page as JSONDownload up to 200 filtered CSV rows
GET /api/datasets/enzyme-transporter-negatives?limit=10&offset=2520

Allowed query parameters

q
Case-insensitive text search over the public fields named for this dataset.
role
Exact recorded role.Values: INDUCER, INHIBITOR, NOT_RECORDED, SUBSTRATE
counterparty
Exact recorded counterparty spelling.
limit / offset
Pagination is required. limit is at most 200; offset is bounded. Set format=csv for the same projected page as a download.

Reuse and corrections

Keep the boundary attached

CC BY 4.0 applies to RNAWiki licenses its selection, schema, structure, and derived projection. Quoted source passages and third-party records retain their original rights.

Cite RNAWiki, this dataset identifier, and the generated date. Keep the “does not mean” statement with any downstream display so a corpus measurement is not mistaken for medical advice.

Read the correction policy